The US Food and Drug Administration has approved a first-of-a-kind pill for the most common form of pancreatic cancer, giving patients a new weapon against one of the deadliest types of the disease. The drug, called daraxonrasib, received expedited approval after clinical evidence showed it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.
The approval marks a milestone in a decades-long effort by drugmakers to target this specific genetic driver. The mutated protein, part of the KRAS family of genes, has long been considered one of the most challenging targets in oncology because of its smooth surface and lack of obvious binding sites for conventional drugs. Daraxonrasib is designed to overcome those obstacles by fitting into a pocket on the protein and locking it in an inactive state.
Pancreatic cancer is notoriously difficult to treat, with a five-year survival rate of around 12% across all stages. Most patients are diagnosed at an advanced stage, when the tumor has already spread and standard chemotherapy offers limited benefit. The new oral therapy provides an alternative for patients whose tumors carry the specific KRAS mutation targeted by the drug, which accounts for the vast majority of pancreatic ductal adenocarcinoma cases.
The FDA granted the approval under its expedited pathways, which are reserved for drugs that address an unmet medical need in serious conditions. The decision was based on data from clinical trials showing meaningful tumor shrinkage and prolonged progression-free survival in patients who had previously received chemotherapy. The agency noted that the drug was generally well tolerated, with side effects including fatigue, nausea, and diarrhea, though some patients experienced more serious adverse events requiring dose adjustment.
Daraxonrasib will be available as an oral tablet taken daily, a significant convenience compared with intravenous chemotherapy regimens that require frequent hospital visits. The manufacturer has announced plans to make the drug available to patients within weeks, and discussions are underway with insurers and healthcare systems to ensure broad access.
Oncologists have welcomed the approval as a step forward in precision medicine for pancreatic cancer, a field that has lagged behind other tumor types in the development of targeted therapies. Researchers are already studying whether daraxonrasib could be combined with other agents, including immunotherapies, to improve outcomes further. Clinical trials are also exploring its use in earlier stages of the disease, where the drug might be given before surgery to shrink tumors and improve the chances of successful resection.
The approval comes amid broader efforts to improve pancreatic cancer outcomes, including earlier detection programs and new screening technologies. While daraxonrasib is not a cure, it represents a meaningful advance for a patient population that has had few options beyond chemotherapy. The FDA has required the manufacturer to conduct post-marketing studies to confirm the drug's benefit and monitor long-term safety in a larger patient population.
